A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin.
Latest Information Update: 24 Dec 2021
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Simeprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms OPERA-1
- Sponsors Janssen R&D Ireland
- 01 Oct 2010 According to a Medivir media release, the results of this trial will be presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
- 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.